This chart shows the NCCN guideline recommendations for patients with advanced or metastatic disease who would be appropriate candidates for intensive therapy. This includes patients who would be expected to have a good tolerance for the therapy and for whom a high tumor response rate would be potentially beneficial. Note that various chemotherapeutic regimens may be used along with the VEGF inhibitor, bevacizumab. In addition, the EGFR inhibitors, cetuximab and panitumumab, are recommended for use in patients with left-sided tumors containing wild-type RAS and BRAF genes.